Viemed Healthcare Completes Share Repurchase Program for $13.2 Million

Viemed Healthcare has completed a share repurchase program, buying back 1,976,441 common shares for approximately $13.2 million at a weighted average price of $6.69 per share. The program was authorized by the Board of Directors to repurchase up to 5% of the total issued and outstanding shares. The company believes in its long-term outlook and is committed to enhancing shareholder value.

Viemed Healthcare Inc. (NASDAQ: VMD), a leader in home-based post-acute respiratory care, has completed its share repurchase program, buying back 1,976,441 common shares for approximately $13.2 million at a weighted average price of $6.69 per share. The program was authorized by the Board of Directors to repurchase up to 5% of the total issued and outstanding shares. The company believes in its long-term outlook and is committed to enhancing shareholder value.

The share repurchase program, announced on June 9, 2025, was executed through open market and block trades, with daily purchases limited to 25% of the previous 4-week average daily volume. CEO Casey Hoyt emphasized that the completion of this program reflects the company's confidence in its long-term outlook and commitment to shareholder value, supported by strong balance sheet and increasing free cash flow.

Viemed Healthcare's financial performance has been robust, with record Q2 2025 financial results showing record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), a 115.1% increase from Q2 2024. The company's Adjusted EBITDA grew 11.5% to $14.3 million. Operational highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260.

The company's strong financial position, with $20 million in cash and $55 million available in credit facilities, supports both its share repurchase program and growth initiatives, including the pending Lehan's Medical acquisition expected to close in Q3 2025. The acquisition adds $25.7 million in revenue and $7.4 million in Adjusted EBITDA from Lehan's 2024 performance, expanding Viemed's geographical footprint with 6 new locations in Illinois and Wisconsin.

Viemed Healthcare maintains a disciplined capital allocation strategy, evident in its share repurchase program and strategic acquisitions, aimed at enhancing shareholder value and strengthening its position in the respiratory care market.